vs
Aardvark Therapeutics, Inc.（AARD）与Arcellx, Inc.（ACLX）财务数据对比。点击上方公司名可切换其他公司
Aardvark Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对炎症、代谢类疾病及罕见病的新型靶向疗法，核心管线聚焦G蛋白偶联受体相关药物，主要服务北美及全球患者群体，开展医药研发领域合作。
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
AARD vs ACLX — 直观对比
营收规模更大
ACLX
是对方的Infinity倍
$0
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $0 | $1.7M |
| 净利润 | $-17.6M | $-58.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -3850.2% |
| 净利率 | — | -3513.4% |
| 营收同比 | — | -89.2% |
| 净利润同比 | — | -23.4% |
| 每股收益（稀释后） | $-0.81 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AARDACLX
| Q4 25 | $0 | $1.7M | ||
| Q3 25 | $0 | $4.9M | ||
| Q2 25 | $0 | $7.6M | ||
| Q1 25 | $0 | $8.1M | ||
| Q4 24 | — | $15.3M | ||
| Q3 24 | — | $26.0M | ||
| Q2 24 | — | $27.4M | ||
| Q1 24 | — | $39.3M |
净利润AARDACLX
| Q4 25 | $-17.6M | $-58.1M | ||
| Q3 25 | $-16.3M | $-55.8M | ||
| Q2 25 | $-14.4M | $-52.8M | ||
| Q1 25 | $-9.3M | $-62.3M | ||
| Q4 24 | — | $-47.1M | ||
| Q3 24 | — | $-25.9M | ||
| Q2 24 | — | $-27.2M | ||
| Q1 24 | — | $-7.2M |
营业利润率AARDACLX
| Q4 25 | — | -3850.2% | ||
| Q3 25 | — | -1248.3% | ||
| Q2 25 | — | -777.4% | ||
| Q1 25 | — | -847.6% | ||
| Q4 24 | — | -348.2% | ||
| Q3 24 | — | -129.1% | ||
| Q2 24 | — | -127.8% | ||
| Q1 24 | — | -40.3% |
净利率AARDACLX
| Q4 25 | — | -3513.4% | ||
| Q3 25 | — | -1127.1% | ||
| Q2 25 | — | -698.6% | ||
| Q1 25 | — | -766.0% | ||
| Q4 24 | — | -308.4% | ||
| Q3 24 | — | -99.4% | ||
| Q2 24 | — | -99.3% | ||
| Q1 24 | — | -18.3% |
每股收益（稀释后）AARDACLX
| Q4 25 | $-0.81 | $-1.01 | ||
| Q3 25 | $-0.75 | $-0.99 | ||
| Q2 25 | $-0.66 | $-0.94 | ||
| Q1 25 | $-0.71 | $-1.13 | ||
| Q4 24 | — | $-0.87 | ||
| Q3 24 | — | $-0.48 | ||
| Q2 24 | — | $-0.51 | ||
| Q1 24 | — | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $110.0M | $450.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $106.6M | $402.4M |
| 总资产 | $117.2M | $604.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AARDACLX
| Q4 25 | $110.0M | $450.3M | ||
| Q3 25 | $126.3M | $461.4M | ||
| Q2 25 | $141.8M | $453.1M | ||
| Q1 25 | $151.3M | $543.3M | ||
| Q4 24 | — | $587.4M | ||
| Q3 24 | — | $574.3M | ||
| Q2 24 | — | $516.7M | ||
| Q1 24 | — | $573.9M |
股东权益AARDACLX
| Q4 25 | $106.6M | $402.4M | ||
| Q3 25 | $122.4M | $440.8M | ||
| Q2 25 | $136.9M | $392.2M | ||
| Q1 25 | $150.7M | $416.9M | ||
| Q4 24 | — | $454.8M | ||
| Q3 24 | — | $483.0M | ||
| Q2 24 | — | $487.2M | ||
| Q1 24 | — | $496.6M |
总资产AARDACLX
| Q4 25 | $117.2M | $604.0M | ||
| Q3 25 | $133.2M | $655.9M | ||
| Q2 25 | $147.5M | $619.1M | ||
| Q1 25 | $157.0M | $648.1M | ||
| Q4 24 | — | $711.3M | ||
| Q3 24 | — | $764.9M | ||
| Q2 24 | — | $734.3M | ||
| Q1 24 | — | $779.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.8M | $-58.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-58.9M |
| 自由现金流率自由现金流/营收 | — | -3563.4% |
| 资本支出强度资本支出/营收 | — | 46.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-212.6M |
8季度趋势，按日历期对齐
经营现金流AARDACLX
| Q4 25 | $-16.8M | $-58.2M | ||
| Q3 25 | $-16.1M | $-49.2M | ||
| Q2 25 | $-9.8M | $-39.7M | ||
| Q1 25 | $-11.4M | $-63.1M | ||
| Q4 24 | — | $-46.0M | ||
| Q3 24 | — | $30.7M | ||
| Q2 24 | — | $-36.2M | ||
| Q1 24 | — | $-31.9M |
自由现金流AARDACLX
| Q4 25 | — | $-58.9M | ||
| Q3 25 | $-16.1M | $-49.5M | ||
| Q2 25 | $-9.9M | $-40.2M | ||
| Q1 25 | — | $-63.9M | ||
| Q4 24 | — | $-47.5M | ||
| Q3 24 | — | $28.4M | ||
| Q2 24 | — | $-39.5M | ||
| Q1 24 | — | $-38.3M |
自由现金流率AARDACLX
| Q4 25 | — | -3563.4% | ||
| Q3 25 | — | -1000.3% | ||
| Q2 25 | — | -532.4% | ||
| Q1 25 | — | -786.4% | ||
| Q4 24 | — | -311.3% | ||
| Q3 24 | — | 109.2% | ||
| Q2 24 | — | -144.1% | ||
| Q1 24 | — | -97.7% |
资本支出强度AARDACLX
| Q4 25 | — | 46.2% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | — | 6.4% | ||
| Q1 25 | — | 9.6% | ||
| Q4 24 | — | 9.8% | ||
| Q3 24 | — | 8.8% | ||
| Q2 24 | — | 11.7% | ||
| Q1 24 | — | 16.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
